Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1551-1559

  Italiano, Antoine ^a,b   Cioffi, Angela ^b,c   Coco, Paola ^d   Maki, Robert G ^b,e   Schöffski, Patrick ^f   Rutkowski, Piotr ^g   Le Cesne, Axel ^c   Duffaud, Florence ^h   Adenis, Antoine ⁱ   Isambert, Nicolas ^j   Bompas, Emmanuelle ^k   Blay, Jean Yves ^l   Casali, Paolo ^c   Keohan, Mary Louise ^b   Toulmonde, Maud ^a   Antonescu, Cristina R ^b   Debiec Rychter, Maria ^f   Coindre, Jean Michel ^a   Bui, Binh ^a  

^a INSTITUT BERGONIÉ   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h TIMONE HOSPITAL   (France)

ⁱ CENTRE OSCAR LAMBRET   (France)

^j CENTRE GEORGES FRANÇOIS LECLERC   (France)

^k CENTRE RENÉ GAUDUCHEAU   (France)

^l CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMATINIB; NILOTINIB; RAPAMYCIN; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PATIENT CARE; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; YOUNG ADULT;

EID: 84862556696     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2120-6     Document Type: Article

References (26)

1. Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.
2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368:1329-38. (Pubitemid 44528723)
3. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45: 1959-68.
4. Hamilton SR, Lauri A, editors. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours. Lyon: IARC; 2000.
5. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.
6. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M, et al. Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS. 2007;115:289-98. (Pubitemid 46743943)
7. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-9. (Pubitemid 46621810)
8. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosom Cancer. 2008;47:853-9.
9. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141-8.
10. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009;125:2991-4.
11. Janeway KA, Kim SY, Lodish M, Nosée V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108:314-8.
12. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64-74.
13. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743-9.
14. Prenen H, Guetens G, de Boeck G, Debiec-Rychter M, Manley P, Schoffski P, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006;77:11-6.
15. Dileo P, Bauer S, Van Den Abbeele A, Morgan JA, George S, Salesi JM, et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST [abstract]. Presented at ASCO gastrointestinal cancers symposium; January 28-30, 2006; San Francisco, CA; Abstract 53.
16. Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009;45:2293-7.
17. Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, et al. A. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011. doi: 10.1002/cncr.26120.
18. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des. 2002;8:2255-7. (Pubitemid 35189898)
19. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:4874-81. (Pubitemid 47294795)
20. Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2011;29 Suppl 4; Abstract 4.
21. National Comprehensive Cancer Network, NCCN Clinical Practice guidelines in oncology: soft tissue sarcoma. Vol 2. 2010 http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp.
22. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2010;21 Suppl 5:v98-v102.
23. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bin Bui N, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3. J Clin Oncol. 2010;28:15s Suppl; Abstr 10017.
24. Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38 Suppl 1:S3-9.
25. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11: 1943-55.
26. George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, et al. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 29:2011 Suppl; Abstract 10007.